Current Environment:

Researcher | Research Overview

Dr. Michelson's research group, the Center for Platelet Research Studies (CPRS), is an internationally recognized, multidisciplinary center for the study of platelets by state-of-the-art methods. The CPRS is an integrated research group that performs basic bench research, translational research, and clinical research on platelets and related aspects of hemostasis and thrombosis.

A particular focus of research in the CPRS is antiplatelet therapy, including characterization of:

  • Novel molecules and mechanisms for therapeutic platelet inhibition
  • The effects of antiplatelet agents on coagulation and inflammation
  • The relationship between the degree of inhibition of platelet function and clinical outcomes (thrombosis vs. hemorrhage)
  • The use of in vitro platelet function tests to guide antiplatelet therapy in order to obtain better clinical outcomes
  • The relationship of platelet function to clinical outcomes in immune thrombocytopenia (ITP)

Researcher | Research Background

Dr. Michelson received his medical degree with honors from the University of Adelaide, Australia and was a Fulbright Scholar at Harvard Medical School. Dr. Michelson is the editor of the textbook "Platelets" (Elsevier/Academic Press). The first edition of "Platelets", published in 2002, was the winner of the Best Book in Medical Science Award from the Association of American Publishers. The 64-chapter, 1300-page third edition was published in 2012.

Selected Publications

  1. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119:4066-4072.
  2. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Journal of the American College of Cardiology 2012;59:1304–1311.
  3. Michelson AD. Advances in antiplatelet therapy. Hematology 2011 (American Society of Hematology Education Program Book), pp 62-69.
  4. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-2228.
  5. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 2010;9:154-169.
  6. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI,Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-2596.
  7. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P,Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:887-968.
  8. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proceedings of the National Academy of Sciences, U.S.A. 1996;93:11877-11882.
  9. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. Journal of Clinical Investigation 1996;97:979-987.

Researcher | Publications